|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, the present data indicated that HMGCS1 may be a novel biomarker, and the combination of targeting HMGCS1 and MEK might be a promising therapeutic strategy for colon cancer patients.
|
31554653 |
2020 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, borussertib displayed antitumor activity in combination with the MEK inhibitor trametinib in patient-derived xenograft models of mutant <i>KRAS</i> pancreatic and colon cancer.
|
30858154 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A <i>MEK1</i><sup>V211D</sup> mutation developed in a patient with <i>BRAF</i><sup>K601E</sup> colon cancer on MEK and EGFR inhibitors.
|
31227518 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we investigated whether combination of 5-FU and a MEK inhibitor had treatment sequence-dependent synergistic effects in KRAS or BRAF mutant colon cancer models.
|
30579838 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that inhibition of the WNT pathway, particularly β-catenin, may bypass resistance to MEK inhibition in human PIK3CA mt colon cancer.
|
30944457 |
2019 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this article we investigate the effects of anti-MEK (mitogen-activated protein kinase) antibody (trametinib) combined with anti-EGFR (cetuximab) on colon cancer cell lines with different RAS statuses.
|
30980281 |
2019 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of MEK Inhibitor and the JAK2-STAT3 Pathway Inhibition for the Therapy of Colon Cancer.
|
30706361 |
2019 |
|
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identify the ERN1-JNK-JUN pathway as a novel regulator of MEK inhibitor response in KRAS mutant colon cancer.
|
30482246 |
2018 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, mechanistic investigations demonstrated that FABP7 exerted its promoting effects on CC cell proliferation and survival through activation of the MEK/ERK signaling pathway.
|
30218856 |
2018 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that mTOR inhibitor resistance in invasive intestinal tumors involves feedback signaling from both cancer epithelial and stromal cells, highlighting the role of tumor microenvironment in drug resistance, and support that simultaneous inhibition of mTOR and EGFR or MEK may be more effective in treating colon cancer.
|
28759045 |
2017 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
|
27655129 |
2016 |
|
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MKK7 was expressed in six out of seven colon cancer cell lines examined but not in non-transformed colon epithelial cells, and its expression was required for the activating phosphorylation of JNK.
|
24533778 |
2014 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors.
|
24685132 |
2014 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings highlight the importance of the MAPK pathway in paclitaxel-induced apoptosis and suggest that a combined treatment with paclitaxel and MEK inhibitors could be an attractive therapeutic strategy against colon cancer.
|
19331159 |
2009 |